The 22nd annual prostate cancer foundation scientific retreat report.
The 22nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat was convened in Washington, D.C. from October 8 to 10, 2015. This event is the foremost scientific conference in the world focusing on basic, translational, and clinical prostate cancer research with the highest potential for accelerating the understanding of prostate cancer biology and improving the lives and outcomes of prostate cancer patients. Topics highlighted during the 2015 Retreat included: (i) new strategies and treatments for localized high-risk, hormone-naïve, oligometastatic, castrate-resistant, and treatment-refractory prostate cancer settings; (ii) the biology and genomics of tumor heterogeneity and tumor evolution; (iii) new understandings on the mechanisms and targeting of oncogenic drivers of prostate cancer; (iv) bioengineering of novel therapies and drug delivery methods; (v) innovative approaches to tumor immunotherapy; (vi) emerging molecular imaging technologies with improved sensitivity and specificity; and (vii) advancements in prognostic and predictive biomarkers and precision medicine strategies. Prostate 76:1037-1052, 2016. © 2016 Wiley Periodicals, Inc.
Prostate Cancer Foundation, Santa Monica, California.
Andrea K
AK
Miyahira
Prostate Cancer Foundation, Santa Monica, California.
Jonathan W
JW
Simons
Prostate Cancer Foundation, Santa Monica, California.
Howard R
HR
Soule
D014408:Biomarkers, Tumor; D003226:Congresses as Topic; D004219:District of Columbia; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D005582:Foundations; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D008297:Male; D057054:Molecular Imaging / Q000379:methods / Q000639:trends; D009362:Neoplasm Metastasis / Q000628:therapy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000235:genetics / Q000628:therapy; D064129:Prostatic Neoplasms, Castration-Resistant / Q000628:therapy; D011944:Receptors, Androgen; D012306:Risk; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D011944:Receptors, Androgen
androgen receptor; diagnosis; prognosis; therapy; tumorigenesis